» Articles » PMID: 36175598

SPLUNC1 Regulates LPS-induced Progression of Nasopharyngeal Carcinoma and Proliferation of Myeloid-derived Suppressor Cells

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2022 Sep 29
PMID 36175598
Authors
Affiliations
Soon will be listed here.
Abstract

Nasopharyngeal carcinoma (NPC) is one of the aggressive malignant tumors with high mortality, and the proliferation of myeloid-derived suppressor cells (MDSCs) could promote the metastasis of NPC through inhibiting the function of T cells. Meanwhile, SPLUNC1 was known to inhibit the malignant behavior of NPC cells, while the detailed function of SPLUNC1 in LPS-modified immune microenvironment of NPC remains unclear. To assess the impact of SPLUNC1 in immune microenvironment during the progression of NPC, NPC cells were exposed to LPS and then co-cultured with MDSCs for 48 h. RT-qPCR and western blot were performed to evaluate the mRNA and protein level of SPLUNC1, CXCL-2 and CXCR-2, respectively. The level of IL-1β, IL-6, TNF-α, PD-L1, Arg-1 and iNOS were tested by ELISA. Meanwhile, the expression of CD33 was tested by flow cytometry. The expression of CXCL-2 and CXCR-2 in NPC cells was higher, compared to that in NP69 cells. In contrast, SPLUNC1 level in NPC cells was much lower than that in NP69 cells. SPLUNC1 level was negatively correlated with CXCL-2 and CXCR-2. Overexpression of SPLUNC1 reversed LPS-induced inflammatory responses and proliferation in NPC cells. In addition, SPLUNC1 upregulation could reverse LPS-induced proliferation of MDSCs in tumor microenvironment. Meanwhile, SPLUNC1 overexpression could regulate CXCL-2/CXCR-2 axis through decreasing CXCL-2 and CXCR-2 protein and mRNA expression. SPLUNC1 regulates LPS-induced progression of nasopharyngeal carcinoma and proliferation of MDSCs. Thus, our study might provide a theoretical basis for discovering new strategies against NPC.

Citing Articles

PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17/β-catenin in nasopharyngeal carcinoma.

Feng R, Guo Y, Chen M, Tian Z, Liu Y, Jiang S J Pathol Transl Med. 2025; 59(1):68-83.

PMID: 39815745 PMC: 11736280. DOI: 10.4132/jptm.2024.11.27.


UBR5 metabolically reprograms nasopharyngeal carcinoma cells to promote glycolysis and M2 polarization via SPLUNC1 signaling.

Liu H, Li Y, Tang L, Sun X, Xie W, Xiao T NPJ Precis Oncol. 2024; 8(1):252.

PMID: 39501021 PMC: 11538528. DOI: 10.1038/s41698-024-00747-y.


Lipopolysaccharide-Educated Cancer-Associated Fibroblasts Facilitate Malignant Progression of Ovarian Cancer Cells via the NF-kB/IL-6/JAK2 Signal Transduction.

Wang D, Li L, Zhang Y, Ye K Mol Biotechnol. 2024; 67(1):317-328.

PMID: 38305842 DOI: 10.1007/s12033-024-01055-3.

References
1.
Miao G, Liu B, Ling K, Peng T, Zhou E, Xie S . Long Noncoding RNA HCP5 Contributes to Nasopharyngeal Carcinoma Progression by Targeting MicroRNA-128-3p. J Oncol. 2022; 2022:5740857. PMC: 9119759. DOI: 10.1155/2022/5740857. View

2.
Hasson A, Jiang W, Benabdallah N, Lu P, Longtine M, Beattie B . Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies. Cancer Biother Radiopharm. 2022; 38(1):15-25. PMC: 9940811. DOI: 10.1089/cbr.2022.0023. View

3.
Liang Y, Zhang Y, Tan X, Qiao H, Liu S, Tang L . A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Nat Commun. 2022; 13(1):2996. PMC: 9151760. DOI: 10.1038/s41467-022-30709-6. View

4.
Lei Y, Luo W, Gong Q, Luo L, Jing W . Long Non-Coding RNA Cancer Susceptibility Candidate 9 Regulates the Malignant Biological Behavior of Nasopharyngeal Carcinoma Cells by Targeting miR-497-5p/Wnt3a/β-catenin Signaling Pathway. Front Oncol. 2022; 12:807052. PMC: 8995468. DOI: 10.3389/fonc.2022.807052. View

5.
Jaiswal A, Yadav J, Makhija S, Sandey M, Suryawanshi A, Mitra A . Short palate, lung, and nasal epithelial clone 1 (SPLUNC1) level determines steroid-resistant airway inflammation in aging. Am J Physiol Lung Cell Mol Physiol. 2021; 322(1):L102-L115. PMC: 8759962. DOI: 10.1152/ajplung.00315.2021. View